Revance Therapeutics (RVNC) Misses Q1 EPS by 7c; Offers FY23 Revenue Guidance

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $49.3 million versus the consensus estimate of $45.73 million.

GUIDANCE:

Revance Therapeutics sees FY2023 revenue of $460-480 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Morgan Stanley Downgrades Melco Resorts (MLCO) to Equalweight
• Wall Street scrambles to lift Micron price targets ahead of earnings